List All Multiple Myeloma Trials

Multiple Myeloma


Carfilzomib + Melphalan/Prednisone for Newly Diagnosed Multiple Myeloma (CLARION Study)
A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Investigator: Edward Libby, MD;   Conditions: Multiple Myeloma;    Status: Closed;   Study ID: NCT01818752

Yttrium Y 90 anti-CD45 monoclonal antibody BC8 + Chemo + TDI before Transplant for Multiple Myeloma (2450)
A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma

Investigator: Bill Bensinger, MD;   Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01503242

Lenalidomide + Bortezomib + Dexamethasone for Multiple Myeloma (2477)
A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)

Investigator: Bill Bensinger, MD;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT01208662

SAR650984 for CD38+ Hematological Malignancies
Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients With Selected CD38+ Hematological Malignancies

Investigator: William Bensinger, MD;   Conditions: Hematological Malignancies;    Status: Recruiting;   Study ID: NCT01084252

MK-3475 for Hematologic Malignancies
A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects With Hematologic Malignancies

Investigator: William I. Bensinger, MD;   Conditions: Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma;    Status: Pending;   Study ID: NCT01953692

GSK2857916 for Relapsed/Refractory Multiple Myeloma (20142069)
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA

Investigator: Edward Libby;   Conditions: Multiple Myeloma;    Status: Recruiting;   Study ID: NCT02064387

NEOD001 + Standard of Care vs. Placebo Plus Standard of Care for Light Chain (AL) Amyloidosis (20150681)
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled. 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis

Investigator: Edward Libby;   Conditions: Amyloidosis;    Status: Recruiting;   Study ID: NCT02312206